Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lymphoma, AIDS-related
Results 1-25 of 36 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TED10893, NCI-2010-02332, U1111-1116-5472, NCT01084252
Vorinostat and Combination Chemotherapy with Rituximab in Treating Patients with HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-075, NCI-2011-02508, AMC #75, CDR0000683379, NCT01193842
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with Stage II-IV HIV-Associated Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-085, NCI-2013-00046, 085, 2014-003678-18, PAMC-085_A05PAMDREVW01, NCT01771107
Methotrexate, Rituximab, Leucovorin Calcium, and Highly Active Antiretroviral Therapy in Treating Patients with AIDS-Related Primary Central Nervous System Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 06-C-0051, NCI-2013-01435, 060051, 339615, NCT00304044, P6720, NCT00267865
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: FDA IND 100712, NCI-2014-00420, NCT00611208
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, 2212, NCT00968630
Rasburicase or Allopurinol in Preventing Tumor Lysis Syndrome in Patients with Hematological Malignancies Undergoing Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2010-0284, NCI-2012-01889, NCI-2010-02082, NCT01200485
Ofatumumab and Bendamustine Hydrochloride with or without Bortezomib in Treating Patients with Untreated Follicular Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CALGB 50904, NCI-2011-02625, CDR0000694298, NCT01286272
Donor Umbilical Cord Blood Transplant After Combination Chemotherapy and Total-Body Irradiation in Treating Younger Patients With High-Risk Hematologic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: UCBT01, NCI-2011-03700, NCT01328496
Allogeneic Transplant in HIV Patients (BMT CTN 0903)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 and over
Trial IDs: BMTCTN0903, NCI-2014-00311, 710, U01HL069294, NCT01410344
Immune Therapy in Treating Patients with Epstein-Barr Virus Lymphoproliferative Disorders or Epstein-Barr Virus-Associated Malignancies
Phase: Phase II
Type: Diagnostic, Treatment
Age: any age
Trial IDs: 11-130, NCI-2012-00594, NCT01498484
Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients with Previously Untreated HIV-Associated Diffuse Large B-Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-068, NCI-2012-01695, 068, NCT01775475
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, EAY131-A, EAY131-B, EAY131-E, EAY131-F, EAY131-G, EAY131-H, EAY131-Q, EAY131-R, EAY131-U, EAY131-V, NCT02465060
Combination Chemotherapy and Rituximab in Treating Patients with Previously Untreated AIDS-Related Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 01-C-0030, NCI-2009-00007, 2890, CDR0000068357, NCT00020384, NCT00006436
Sirolimus or Vorinostat in Combination with Hydroxychloroquine in Treating Patients with Advanced or Metastatic Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0588, NCI-2011-00303, NCT01266057
Belinostat in Treating Patients with Liver Cancer or Liver Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 11-C-0060, NCI-2013-01474, 110060, P10739, 8846, NCT01273155
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B1641001, NCI-2012-00880, 2011-002799-17, NCT01307267
T-Lymphocytes in Treating Patients with Active or Relapsed Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: BCM H 27471, NCI-2012-00680, CDR0000724621, H-27471-TACTAL, NCT01556269, 9101, NCT01333046
Pazopanib Hydrochloride and Vorinostat in Treating Patients with Advanced Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0051, NCI-2011-00771, NCT01339871
PU-H71 in Treating Patients With Advanced Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-041, NCI-2011-01341, NCT01393509
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IMGN0301, NCI-2013-01209, 0301, NCT01534715
Fenretinide and Safingol in Treating Patients With Relapsed Malignancies
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SPOC-2010-002, NCI-2012-00816, Mod6_STU 042011-132, SCCC-12Y11, NCT01553071
Start Over